Stoke Therapeutics (STOK) Change in Accured Expenses (2018 - 2026)

Stoke Therapeutics' Change in Accured Expenses history runs 9 years deep, the most recent figure standing at -$15.7 million for Q1 2026.

• On a quarterly basis, Change in Accured Expenses fell 431.55% year-over-year to -$15.7 million in Q1 2026; TTM through Mar 2026 was $829000.0, a 91.5% decrease from a year earlier, with the FY2025 full-year figure at $21.3 million, up 589.41% from the prior year.
• Change in Accured Expenses declined to -$15.7 million in Q1 2026 per STOK's latest filing, from $8.9 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $8.9 million in Q4 2025 and bottomed at -$15.7 million in Q1 2026.
• The 5-year median for Change in Accured Expenses is $351000.0 (2023), against an average of $112941.2.
• Across the five-year window, Change in Accured Expenses tumbled 677.39% in 2023 and jumped 751.67% in 2025, its largest moves.
• Year by year, Change in Accured Expenses stood at $199000.0 in 2022, then tumbled by 677.39% to -$1.1 million in 2023, then soared by 289.64% to $2.2 million in 2024, then jumped by 308.54% to $8.9 million in 2025, then tumbled by 276.58% to -$15.7 million in 2026.
• Per Business Quant, the three latest STOK Change in Accured Expenses figures stand at -$15.7 million (Q1 2026), $8.9 million (Q4 2025), and $4.9 million (Q3 2025).